Dublin, Dec. 12, 2024 (GLOBE NEWSWIRE) -- The "Peptide and Oligonucleotide CDMO Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.
The global peptide and oligonucleotide CDMO market is expected to reach an estimated $5 billion by 2030 with a CAGR of 11.3% from 2024 to 2030. The major drivers for this market are the growing popularity of customized medicine, increasing concern about uncommon diseases, and the rise in emphasis on peptide antivirals.
The future of the global peptide and oligonucleotide CDMO market looks promising with opportunities in the pharmaceutical company and biopharmaceutical company markets.
- Within the product category, the peptide segment will remain a larger segment over the forecast period.
- Within the end-use category, biopharmaceutical companies will remain a larger segment over the forecast period.
- In terms of regions, North America will remain the largest region over the forecast period.
Features of this Peptide and Oligonucleotide CDMO Market Report:
- Market Size Estimates: Peptide and oligonucleotide CDMO market size estimation in terms of value ($B).
- Trend and Forecast Analysis: Market trends (2018 to 2023) and forecasts (2024 to 2030) by various segments and regions.
- Segmentation Analysis: Peptide and oligonucleotide CDMO market size by product, service type, end use, and region in terms of value ($B).
- Regional Analysis: Peptide and oligonucleotide CDMO market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
- Growth Opportunities: Analysis of growth opportunities in different products, service types, end uses, and regions for the peptide and oligonucleotide CDMO market.
- Strategic Analysis: This includes M&A, new product development, and competitive landscape of the peptide and oligonucleotide CDMO market.
- Analysis of competitive intensity of the industry based on Porter's Five Forces model.
This report answers the following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the peptide and oligonucleotide CDMO market by product (peptides and oligonucleotides), service type (contract development and contract manufacturing), end use (pharmaceutical companies, biopharmaceutical companies, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
Key Topics Covered
1. Executive Summary
2. Global Peptide and Oligonucleotide CDMO Market: Market Dynamics
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. Market Trends and Forecast Analysis from 2018 to 2030
3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Peptide and Oligonucleotide CDMO Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global Peptide and Oligonucleotide CDMO Market by Product
3.3.1: Peptides
3.3.2: Oligonucleotides
3.4: Global Peptide and Oligonucleotide CDMO Market by Service Type
3.4.1: Contract Development
3.4.2: Contract Manufacturing
3.5: Global Peptide and Oligonucleotide CDMO Market by End Use
3.5.1: Pharmaceutical Companies
3.5.2: Biopharmaceutical Companies
3.5.3: Others
4. Market Trends and Forecast Analysis by Region from 2018 to 2030
4.1: Global Peptide and Oligonucleotide CDMO Market by Region
4.2: North American Peptide and Oligonucleotide CDMO Market
4.3: European Peptide and Oligonucleotide CDMO Market
4.4: APAC Peptide and Oligonucleotide CDMO Market
4.5: RoW Peptide and Oligonucleotide CDMO Market
5. Competitor Analysis
5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter's Five Forces Analysis
6. Growth Opportunities and Strategic Analysis
6.1: Growth Opportunity Analysis
6.1.1: Growth Opportunities for the Global Peptide and Oligonucleotide CDMO Market by Product
6.1.2: Growth Opportunities for the Global Peptide and Oligonucleotide CDMO Market by Service Type
6.1.3: Growth Opportunities for the Global Peptide and Oligonucleotide CDMO Market by End Use
6.1.4: Growth Opportunities for the Global Peptide and Oligonucleotide CDMO Market by Region
6.2: Emerging Trends in the Global Peptide and Oligonucleotide CDMO Market
6.3: Strategic Analysis
6.3.1: New Product Development
6.3.2: Capacity Expansion of the Global Peptide and Oligonucleotide CDMO Market
6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Peptide and Oligonucleotide CDMO Market
6.3.4: Certification and Licensing
7. Company Profiles of Leading Players
7.1: PolyPeptide Group
7.2: STA Pharmaceutical
7.3: Bachem
7.4: Creative Peptides
7.5: Aurigene Pharmaceutical Services
7.6: Merck
7.7: EUROAPI
7.8: Curia Global
7.9: CordenPharm
7.10: Sylentis
For more information about this report visit https://www.researchandmarkets.com/r/iyuj39
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
